News
DSGN
3.780
+0.53%
0.020
Weekly Report: what happened at DSGN last week (0415-0419)?
Weekly Report · 6d ago
Weekly Report: what happened at DSGN last week (0408-0412)?
Weekly Report · 04/15 09:07
Weekly Report: what happened at DSGN last week (0401-0405)?
Weekly Report · 04/08 09:08
Weekly Report: what happened at DSGN last week (0325-0329)?
Weekly Report · 04/01 09:08
Wednesday 3/27 Insider Buying Report: SNPS, DSGN
NASDAQ · 03/27 17:36
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Insider transactions for penny stocks indicate confidence or concern around the company's prospects. FTC Solar, Inc. And Ocuphire Pharma have recently had notable insider transactions. The Dow Jones index closed lower by over 150 points on Monday. FTC solar and Design Therapeutics are among the recent penny stocks with notable insider trades.
Benzinga · 03/26 11:37
Weekly Report: what happened at DSGN last week (0318-0322)?
Weekly Report · 03/25 09:08
Hold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program Updates
TipRanks · 03/21 06:18
Design Therapeutics, Inc.: Navigating Liquidity Risks Amidst Bank Failures
TipRanks · 03/21 06:00
Design Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Dow Jones · 03/20 15:08
RBC Capital Reiterates Sector Perform on Design Therapeutics, Maintains $4 Price Target
Benzinga · 03/20 14:57
Design Therapeutics Price Target Maintained With a $5.00/Share by Wedbush
Dow Jones · 03/20 14:45
Wedbush Reiterates Neutral on Design Therapeutics, Maintains $5 Price Target
Benzinga · 03/20 14:35
Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)
TipRanks · 03/20 12:50
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
TipRanks · 03/20 11:17
Design Therapeutics (DSGN) Gets a Hold from Piper Sandler
TipRanks · 03/20 11:17
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
Design Therapeutics reported earnings per share of -21 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -31 cents. Design Therapeutic reported results for the last quarter of 2013.
Investorplace · 03/20 00:53
Design Therapeutics GAAP EPS of -$0.21 beats by $0.11
Seeking Alpha · 03/19 20:07
*Design Therapeutics: IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy With Phase 1 Development to Start in 2024 >DSGN
Dow Jones · 03/19 20:03
More
Webull provides a variety of real-time DSGN stock news. You can receive the latest news about Design Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.